Odyssey Therapeutics (NASDAQ:ODTX) Stock Bumped Up to “Strong-Buy” by UBS Group

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by equities research analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

A number of other research firms have also recently weighed in on ODTX. Raymond James Financial initiated coverage on Odyssey Therapeutics in a report on Thursday, October 8th. They set an “outperform” rating and a $42.00 price target on the stock. Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. JPMorgan Chase & Co. increased their price target on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings started coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. Finally, Oppenheimer restated an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.33.

Odyssey Therapeutics Stock Performance

Odyssey Therapeutics stock opened at $17.24 on Monday. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05. The business has a 50-day simple moving average of $22.71.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, research analysts expect that Odyssey Therapeutics will post -6.08 earnings per share for the current year.

Institutional Investors Weigh In On Odyssey Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in shares of Odyssey Therapeutics in the second quarter worth $4,162,000. State Street Corp bought a new position in Odyssey Therapeutics in the second quarter worth $1,477,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Odyssey Therapeutics during the 2nd quarter valued at about $601,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.